Antiarthritic effects of the antispermatogenic agent 2,3-dihydro-(1-naphthyl)-4-(1H)-quinazolinone (U-29,409).
D000284:Administration, Oral; D000818:Animals; D001168:Arthritis / Q000139:chemically induced / Q000188:drug therapy*; D001835:Body Weight; D002351:Carrageenan; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004304:Dosage Forms; D004357:Drug Synergism; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy*; D005260:Female; D007659:Ketones / Q000627:therapeutic use; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use; D009929:Organ Size; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D012737:Sex Factors
D004304:Dosage Forms; D007659:Ketones; D009281:Naphthalenes; D011799:Quinazolines; D003520:Cyclophosphamide; D002351:Carrageenan